Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial
Authors: Lisa Seekircher, Zoltán Bánki, Janine Kimpel, Annika Rössler, Helena Schäfer, Barbara Falkensammer, David Bante, Lukas Forer, Sebastian Schönherr, Teresa Harthaller, Magdalena Sacher, Cornelia Ower, Lena Tschiderer, Hanno Ulmer, Florian Krammer, Dorothee von Laer, Wegene Borena, Peter Willeit, Zoltán Bánki, Janine Kimpel, Annika Rössler, Helena Schäfer, Barbara Falkensammer, David Bante, Florian Krammer, Dorothee von Laer, Wegene Borena, Lukas Forer, Sebastian Schönherr, Magdalena Sacher, Cornelia Ower, Teresa Harthaller, Bianca Neurauter, Eva Hochmuth, Luiza Hoch, Maria Huber, Brigitte Müllauer, Evelyn Peer, Lisa-Maria Raschbichler, Albert Falch, Sabine Embacher-Aichhorn, Kathrin Becker, Lisa Seekircher, Lena Tschiderer, Hanno Ulmer, Peter Willeit
Journal: The Lancet Microbe (2023)

BackgroundCorrelates of protection could help to assess the extent to which a person is protected from SARS-CoV-2 infection after vaccination (so-called breakthrough infection). We aimed to clarify associations of antibody and T-cell responses after vaccination against COVID-19 with risk of a SARS-CoV-2 breakthrough infection and whether measurement of these responses enhances risk prediction.MethodsWe did an open-label, phase 4 trial in two community centres in the Schwaz district of the Federal State of Tyrol, Austria, before the emergence of the omicron (B.1.1.529) variant of SARS-CoV-2. We included individuals (aged ≥16 years) a mean of 35 days (range 27–43) after they had received a second dose of the BNT162b2 (Pfizer–BioNTech) COVID-19 vaccine. We quantified associations between immunological parameters and breakthrough infection and assessed whether information on these parameters improves risk discrimination. The study is registered with the European Union Drug Regulating Authorities Clinical Trials Database, 2021-002030-16.Findings2760 individuals (1682 [60·9%] female, 1078 [39·1%] male, mean age 47·4 years [SD 14·5]) were enrolled into this study between May 15 and May 21, 2021, 712 (25·8%) of whom had a previous SARS-CoV-2 infection. Over a median follow-up of 5·9 months, 68 (2·5%) participants had a breakthrough infection. In models adjusted for age, sex, and previous infection, hazard ratios for breakthrough infection for having twice the immunological parameter level at baseline were 0·72 (95% CI 0·60–0·86) for anti-spike IgG, 0·80 (0·70–0·92) for neutralising antibodies in a surrogate virus neutralisation assay, 0·84 (0·58–1·21) for T-cell response after stimulation with a CD4 peptide pool, and 0·77 (0·54–1·08) for T-cell response after stimulation with a combined CD4 and CD8 peptide pool. For neutralising antibodies measured in a nested case-control sample using a pseudotyped virus neutralisation assay, the corresponding odds ratio was 0·78 (0·62–1·00). Among participants with previous infection, the corresponding hazard ratio was 0·73 (0·61–0·88) for anti-nucleocapsid Ig. Addition of anti-spike IgG information to a model containing information on age and sex improved the C-index by 0·085 (0·027–0·143).InterpretationIn contrast to T-cell response, higher levels of binding and neutralising antibodies were associated with a reduced risk of breakthrough SARS-CoV-2 infection. The assessment of anti-spike IgG enhances the prediction of incident breakthrough SARS-CoV-2 infection and could therefore be a suitable correlate of protection in practice. Our phase 4 trial measured both humoral and cellular immunity and had a 6-month follow-up period; however, the longer-term protection against emerging variants of SARS-CoV-2 remains unclear.FundingNone.